Literature DB >> 12732356

The effect of valproic acid on drug and steroid glucuronidation by expressed human UDP-glucuronosyltransferases.

Brian T Ethell1, Gail D Anderson, Brian Burchell.   

Abstract

Valproic acid glucuronidation kinetics were carried our with three human UGT isoforms: UGT1A6, UGT1A9, and UGT2B7 as well as human liver and kidney microsomes. The glucuronidation of valproic acid was typified by high K(m) values with microsomes and expressed UGTs (2.3-5.2mM). The ability of valproic acid to interact with the glucuronidation of drugs, steroids and xenobiotics in vitro was investigated using the three UGT isoforms known to glucuronidate valproic acid. In addition to this the effect of valproic acid was investigated using two other UGT isoforms: UGT1A1 and UGT2B15 which do not glucuronidate valproic acid. Valproic acid inhibited UGT1A9 catalyzed propofol glucuronidation in an uncompetitive manner and UGT2B7 catalyzed AZT glucuronidation competitively (K(i)=1.6+/-0.06mM). Valproate significantly inhibited UGT2B15 catalyzed steroid and xenobiotic glucuronidation although valproate was not a substrate for this UGT isoform. No significant inhibition of UGT1A1 or UGT1A6 by valproic acid was observed. These data indicate that valproic acid inhibition of glucuronidation reactions is not always due to simple competitive inhibition of substrates.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12732356     DOI: 10.1016/s0006-2952(03)00076-5

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  27 in total

1.  Influence of UDP-glucuronosyltransferase polymorphisms on valproic acid pharmacokinetics in Chinese epilepsy patients.

Authors:  Xiao-Man Chu; Li-Fang Zhang; Guang-Ji Wang; Shen-Ning Zhang; Jia-Hui Zhou; Hai-Ping Hao
Journal:  Eur J Clin Pharmacol       Date:  2012-04-05       Impact factor: 2.953

2.  In vitro changes in the proportion of protein-unbound-free propofol induced by valproate.

Authors:  Minako Ishii-Maruhama; Hitoshi Higuchi; Mai Nakanou; Yuka Honda-Wakasugi; Akiko Yabuki-Kawase; Shigeru Maeda; Takuya Miyawaki
Journal:  J Anesth       Date:  2018-07-30       Impact factor: 2.078

3.  Effects of ketoconazole and valproic acid on the pharmacokinetics of the next generation NNRTI, lersivirine (UK-453,061), in healthy adult subjects.

Authors:  Grant Langdon; John Davis; Gary Layton; Chew-Lan Chong; Georges Weissgerber; Manoli Vourvahis
Journal:  Br J Clin Pharmacol       Date:  2012-05       Impact factor: 4.335

4.  A population pharmacokinetic model of valproic acid in pediatric patients with epilepsy: a non-linear pharmacokinetic model based on protein-binding saturation.

Authors:  Junjie Ding; Yi Wang; Weiwei Lin; Changlian Wang; Limei Zhao; Xingang Li; Zhigang Zhao; Liyan Miao; Zheng Jiao
Journal:  Clin Pharmacokinet       Date:  2015-03       Impact factor: 6.447

Review 5.  Juvenile myoclonic epilepsy: epidemiology, pathophysiology, and management.

Authors:  Timothy E Welty
Journal:  Paediatr Drugs       Date:  2006       Impact factor: 3.022

6.  Lack of pharmacokinetic interactions between steady-state zonisamide and valproic acid in patients with epilepsy.

Authors:  Isabelle Ragueneau-Majlessi; Rene H Levy; Martin Brodie; David Smith; Jaymin Shah; John S Grundy
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 6.447

7.  Valproic acid pathway: pharmacokinetics and pharmacodynamics.

Authors:  Yogita Ghodke-Puranik; Caroline F Thorn; Jatinder K Lamba; J Steven Leeder; Wen Song; Angela K Birnbaum; Russ B Altman; Teri E Klein
Journal:  Pharmacogenet Genomics       Date:  2013-04       Impact factor: 2.089

8.  Effect of aging on glucuronidation of valproic acid in human liver microsomes and the role of UDP-glucuronosyltransferase UGT1A4, UGT1A8, and UGT1A10.

Authors:  Upendra A Argikar; Rory P Remmel
Journal:  Drug Metab Dispos       Date:  2008-10-06       Impact factor: 3.922

9.  Age- and Genotype-Dependent Variability in the Protein Abundance and Activity of Six Major Uridine Diphosphate-Glucuronosyltransferases in Human Liver.

Authors:  Deepak Kumar Bhatt; Aanchal Mehrotra; Andrea Gaedigk; Revathi Chapa; Abdul Basit; Haeyoung Zhang; Prachi Choudhari; Mikael Boberg; Robin E Pearce; Roger Gaedigk; Ulrich Broeckel; J Steven Leeder; Bhagwat Prasad
Journal:  Clin Pharmacol Ther       Date:  2018-07-12       Impact factor: 6.875

Review 10.  Requirements for generic anti-epileptic medicines: a regulatory perspective.

Authors:  Marc Maliepaard; Yechiel A Hekster; Arnoud Kappelle; Eugène P van Puijenbroek; André J Elferink; Jan Welink; Christine C Gispen-de Wied; Frits J F Lekkerkerker
Journal:  J Neurol       Date:  2009-07-15       Impact factor: 4.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.